https://orcid.org/0000-0002-7413-2773
About the Authors
- Darrell Pilling
-
Roles Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review & editing
* E-mail: dpilling@bio.tamu.edu (DP); rgomer@tamu.edu (RHG)
Affiliation Department of Biology, Texas A&M University, College Station, TX, United States of America
- Tejas R. Karhadkar
-
Roles Investigation, Writing – review & editing
Affiliation Department of Biology, Texas A&M University, College Station, TX, United States of America
- Richard H. Gomer
-
Roles Conceptualization, Funding acquisition, Investigation, Supervision, Writing – original draft, Writing – review & editing
* E-mail: dpilling@bio.tamu.edu (DP); rgomer@tamu.edu (RHG)
Affiliation Department of Biology, Texas A&M University, College Station, TX, United States of America
Competing Interests
Texas A&M University has published patent applications on the use of CD209 ligands (United States Patent Application 20160272713) and sialidase inhibitors (United States Patent Application 20190201485) to regulate fibrosis. DP, TRK, and RHG are inventors on pending patent applications for the use of CD209 ligands and sialidase inhibitors as anti-inflammatory and/or anti-obesity compounds. This does not alter our adherence to PLOS ONE policies on sharing data and materials.